Enabling T cell immunotherapy 

Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.

Learn More
ezgif.com-gif-maker (1)
Benefits of the µVS Delivery System™


Easy-to-integrate with existing research, clinical and commercial workflows with standard reagents.



µVS devices can be readily manufactured at scales of >2K devices per day.



Cells are processed at 1~5M per second and soon to be >50M cells per second.



Each 5 x 10 mm device can process >50M cells with a >1B cell device in development.



µVS is optimised to yield the maximum amount of recovered, viable and modified cells.



µVS processing results in minimal perturbation of the T cell state for high quality cells.

State of the µVS Delivery System™

The µVS Delivery System™ is currently available for Research Use Only. A clinical system is in development and will be regulated as a tool for biologics manufacturing. Both systems are developed in an ISO 13485-compliant manner and all materials in the flow path are medical-grade or USP Class VI implantable-grade. µVS devices for high-throughput screening of small volumes based on the well plate format are also in development.

Learn More


Interested in using the µVS Delivery System™?

Equipment Trials

Trial the µVS Delivery SystemTM for 3- to 6-months

Ask Us

Research Services

Have us develop a kit for another cell type or construct

Ask Us


Tell us how we can help you reach your goals

Ask Us

Have questions? Send us a message

You can also reach us by emailing to hello@indeelabs.com